Trial Profile
A 24-week Prospective, Double Blind, Randomized, Placebo-controlled Pilot Study of 9 mg/Day Rivastigmine in Patients With Vascular Cognitive Impairment Not Dementia to Evaluate Efficacy, Safety and Tolerability in Asian Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Feb 2017
Price :
$35
*
At a glance
- Drugs Rivastigmine (Primary)
- Indications Cognition disorders
- Focus Therapeutic Use
- Acronyms RIVIVE
- 01 Apr 2010 Results published in Acta Neurologica Scandinavica.
- 26 May 2008 New trial record.